Please assess the completion status of the following clinical trial:

Trial Title: Vaccination Plus Ontak in Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Melanoma with evidence of metastatic disease~* Life expectancy of at least 12 weeks.~* Karnofsky performance status index of greater than or equal to 80%.~* Adequate hematopoietic, renal, and hepatic function, defined as:~* Patient must express HLA-A2~* Tumor biopsy: patient must agree to undergo biopsy of accessible tumor before and after therapy, when feasible, to study tumor cell properties and characteristics of immune cells.~* EKG without evidence of arrhythmia or changes that indicate acute ischemia.~* Pulse oximetry showing oxygen saturation of at least 90% on room air.~Exclusion Criteria:~* Significant cardiovascular disease, or cardiac arrhythmia requiring medical intervention.~* Pregnant or nursing women.~* Biological therapy in the 4 weeks prior to the start of dosing.~* Patients with intrinsic immunosuppression, including seropositivity for HIV antibody.~* Serious concurrent infection, including active tuberculosis, hepatitis B, or hepatitis C.~* Concurrent systemic corticosteroids (except physiologic replacement doses)or other immunosuppressive drugs (eg. cyclosporin A).~* Psychiatric illness that may make compliance to the clinical protocol unmanageable or may compromise the ability of the patient to give informed consent.~* Active or history of autoimmune disease~* Active gastrointestinal bleeding or uncontrolled peptic ulcer disease.~* Presence of untreated brain metastases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine Alone (Type: EXPERIMENTAL): Subjects received vaccine immunization injected intra-dermally or subcutaneously on day 1. The vaccine was an emulsification consisting of 250 mcg each of the following peptides: Melan-A, gp100, MAGE-3, and NA17 as well as GM-CSF 125 mcg and Montanide. A second and third vaccination was given at 2 weeks and 4 weeks after the first. If there was no evidence of cancer progression, additional courses of three vaccinations administered at 2 week intervals were administered until disease progression.
- Vaccine plus Ontak (Type: EXPERIMENTAL): Subjects in Vaccine plus Ontak received the same vaccination strategy as Vaccine alone group but additionally received a single dose of denileukin diftitox(18 mcg/kg) 4 days prior to the first vaccine administration

Based on this trial design, predict the completion outcome and termination type (if applicable).